Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4B | O94953 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL595228 | 0.93 | KDM4A (0.36) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL5989426 | 0.93 | KDM4A (0.36) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL2676957 | 0.91 | KDM4A (0.35) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL7787939 | 0.85 | KDM4A (0.34) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL3157 | 0.85 | — | — | |
| Purine SCHEMBL2120547 | 0.85 | KDM4A (0.38) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL6421376 | 0.85 | KDM4A (0.38) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL29456595 | 0.85 | — | — | |
| Purine SCHEMBL311318 | 0.83 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL7787135 | 0.83 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2022-09-01 | — | — | US | disclosed |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3926046-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3354656-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3372684-B1 | SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER | SIRNA THERAPEUTICS INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10584335-B2 | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer | SIRNA THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2019-08-01 | — | — | US | disclosed |
| US-10351852-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2003070895-A2 | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070912-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070884-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070742-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070885-A2 | SHORT INTERFERING NUCLEIC ACID INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070197-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070910-A2 | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070750-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS | SIRNA THERAPEUTICS, INC (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030148507-A1 | RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA | RIBOZYME PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030143732-A1 | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | KDM4A 4273/4885KDM4B 4473/4885KDM5C 3905/4885 |
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SRRT, SNRPE | KDM4A 4685/4885KDM4B 4753/4885KDM5C 4601/4885 |
| US-20030143732-A1 | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA | ADORA1, ADORA3, ADORA2A | KDM4A 3612/4885KDM4B 4295/4885KDM5C 3856/4885 |
| US-20030148507-A1 | RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA | PTGDR, PTGDR2, HPGDS | KDM4A 4769/4885KDM4B 4814/4885KDM5C 4499/4885 |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | KDM4A 4273/4885KDM4B 4473/4885KDM5C 3905/4885 |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SNRPE, SRRT | KDM4A 4273/4885KDM4B 4473/4885KDM5C 3905/4885 |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | KDM4A 4273/4885KDM4B 4473/4885KDM5C 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.